Skip to content
DE

GlucagonPeptide hormone and rescue medicine

Glucagon is a hormone released by pancreatic alpha cells. As a medicine, it can help reverse severe hypoglycaemia by prompting the liver to release glucose.

What is Glucagon?

Glucagon is a hormone made by pancreatic alpha cells. Medicines containing glucagon are used to rescue severe hypoglycaemia, with injectable and nasal products requiring their own instructions. 1 3 4

How it works

Glucagon signals the liver to release glucose, countering a dangerously low blood-glucose level. A response depends partly on the liver’s glycogen stores. 3 4

Effects studied

Rescue from severe hypoglycaemia

Glucagon products can raise glucose when someone cannot safely manage the episode themselves. Nasal and injectable preparations have been studied as distinct rescue options.

Evidence: Clinical comparison and product-specific evidence. 2 3 4

What does the evidence show?

The archive includes product information and a study of nasal delivery. Different formulations have their own instructions and eligibility; evidence for one presentation does not make devices interchangeable.

The liver is central to the response

Insulin and glucagon help regulate blood glucose in different ways. Glucagon signals the liver to make glucose available to the circulation. Its effectiveness therefore depends partly on the person’s metabolic circumstances, including available glycogen. It is not the same hormone or drug class as GLP-1 treatments.

Why delivery options matter

Glucagon products can use different routes and preparation steps, including injectable and nasal presentations. Research on a nasal product asks whether that specific preparation produces an adequate response; it does not establish that any powder or peptide with the same name can be used in the same way. 2

Rescue treatment and follow-up

Someone with severe hypoglycaemia may need help from another person and urgent medical attention. A rescue product works best within a prepared plan that follows its actual instructions. Recovery also needs follow-up, because the insulin, medicine or illness that contributed to the episode may still be relevant.

What the product information adds

Nausea and vomiting are recognised concerns, and some medical conditions change the risk assessment. Insulinoma and pheochromocytoma are examples addressed in glucagon information. Prolonged fasting or depleted stores can also complicate response. The current information for the specific product is needed to assess these risks and limitations. 1 3

Safety & status

Nausea and vomiting can occur. Certain endocrine tumours, including insulinoma and pheochromocytoma, require particular attention. Prolonged fasting can reduce available glucose stores and limit the response. 3 4

Country and product status

This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.

Frequently asked questions

Is glucagon the same as a GLP-1 medicine?

No. Despite the related names, rescue glucagon and GLP-1 receptor agonists have different purposes and pharmacology.

Are nasal and injectable products interchangeable in use?

They serve a similar rescue purpose but use different devices and instructions. The exact product matters. 2 3 4

Further reading

Concept illustration for Glucagon.GuideGlucagon: effects, uses and side effectsGlucagon raises blood glucose and is used as an emergency medicine for severe hypoglycemia. How it works, which uses are approved in the United States and its risks.Read the article

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

  1. Glucagon: www.novomedlink.com reference Reference or product information · Retained archive reference; not independently checked for this draft.
  2. Glucagon: paper 10.2337/dc15-1498 Research reference · Retained archive reference; not independently checked for this draft.
  3. Glucagon: www.accessdata.fda.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
  4. Glucagon: www.accessdata.fda.gov reference Reference or product information · Retained archive reference; not independently checked for this draft.
Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.